标题
An urgent call to raise the bar in oncology
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-08-16
DOI
10.1038/s41416-021-01495-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
- (2021) Laila A Gharzai et al. LANCET ONCOLOGY
- Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada
- (2021) Daniel E. Meyers et al. JAMA Internal Medicine
- Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality Rates
- (2021) Harpreet Singh et al. JAMA Oncology
- An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries
- (2021) J. Connor Wells et al. JAMA Oncology
- Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
- (2021) Angela K. Green et al. JAMA Network Open
- Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life
- (2021) Vanessa Arciero et al. JAMA Network Open
- Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
- (2021) Joseph C. Del Paggio et al. JAMA Oncology
- Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study
- (2021) Samer Al Hadidi et al. LEUKEMIA & LYMPHOMA
- Flawed trials for cancer
- (2020) I.F. Tannock et al. ANNALS OF ONCOLOGY
- Enhancing global access to cancer medicines
- (2020) Javier Cortes et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018
- (2020) Eriko Sumi et al. CLINICAL THERAPEUTICS
- Role of Hospice Care at the End of Life for People With Cancer
- (2020) David C. Currow et al. JOURNAL OF CLINICAL ONCOLOGY
- Our best weapons against cancer are not magic bullets
- (2020) Vinay Prasad NATURE
- Recent progress in treating advanced prostate cancer
- (2020) Theodore Gourdin CURRENT OPINION IN ONCOLOGY
- Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas
- (2020) William D. Tap et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Generating comparative evidence on new drugs and devices after approval
- (2020) Andrea Cipriani et al. LANCET
- Generating comparative evidence on new drugs and devices before approval
- (2020) Huseyin Naci et al. LANCET
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
- (2020) Kerstin N Vokinger et al. LANCET ONCOLOGY
- Informative censoring — a neglected cause of bias in oncology trials
- (2020) Arnoud J. Templeton et al. Nature Reviews Clinical Oncology
- Patients’ understanding of oncology clinical endpoints: A literature review
- (2020) Vanessa Boudewyns et al. PATIENT EDUCATION AND COUNSELING
- Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
- (2020) Fernando Gomez-Peralta et al. BMJ Open Diabetes Research & Care
- Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
- (2020) Consolación Molto et al. CANCER
- Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
- (2020) Patricia A. H. Hamers et al. INTERNATIONAL JOURNAL OF CANCER
- The Response Rate of Alternative Treatments for Drugs Approved On the Basis of Response Rate
- (2020) Alyson Haslam et al. INTERNATIONAL JOURNAL OF CANCER
- Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
- (2020) Talal Hilal et al. JAMA Internal Medicine
- Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States
- (2020) MAXIMILIAN SALCHER‐KONRAD et al. MILBANK QUARTERLY
- Progress in Cancer Research, Prevention, and Care
- (2020) Richard L. Schilsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Getting the Right Evidence After Drug Approval
- (2020) Rick A. Vreman et al. Frontiers in Pharmacology
- Oncology’s “Hockey Stick” Moment for the Cost of Cancer Drugs—The Climate Is About to Change
- (2020) Blase N. Polite et al. JAMA Oncology
- Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019
- (2020) Marissa H. Elliott et al. JAMA Internal Medicine
- Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review
- (2020) Rajshekhar Chakraborty et al. Lancet Haematology
- Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation
- (2020) Mark J. Ratain et al. JAMA Oncology
- Recent Advances in the Treatment of Patients with Multiple Myeloma
- (2020) Mario A. Legarda et al. Cancers
- Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
- (2020) Patrick C. DeMartino et al. JAMA Internal Medicine
- Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
- (2020) Pierre-Marie Morice et al. Lancet Haematology
- Evaluating New Rules on Transparency in Cancer Research and Drug Development
- (2019) Thomas J. Hwang et al. JAMA Oncology
- Academia and industry: allocating credit for discovery and development of new therapies
- (2019) Jeffrey S. Flier JOURNAL OF CLINICAL INVESTIGATION
- Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials
- (2019) Derek Kyte et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
- (2019) Emerson Y. Chen et al. JAMA Internal Medicine
- An International Perspective on Drugs for Cancer
- (2019) Richard Lehman et al. JAMA Internal Medicine
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
- (2019) Bishal Gyawali et al. JAMA Internal Medicine
- An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
- (2019) Emerson Y. Chen et al. JAMA Internal Medicine
- The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis
- (2019) Joseph C Del Paggio et al. LANCET ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- (2019) Huseyin Naci et al. BMJ-British Medical Journal
- Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
- (2019) Jonathan M. Loree et al. JAMA Oncology
- Purchasing silence
- (2018) I F Tannock et al. ANNALS OF ONCOLOGY
- Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings
- (2018) Michael J. Hayes et al. HASTINGS CENTER REPORT
- The Proposal to Lower P Value Thresholds to .005
- (2018) John P. A. Ioannidis JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines
- (2018) Thomas J. Hwang et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
- (2018) Jeffrey Wagner et al. BMJ-British Medical Journal
- Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
- (2018) Jeffrey Wagner et al. BMJ-British Medical Journal
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics
- (2018) Julia A. Beaver et al. JAMA Oncology
- Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials
- (2018) Cole Wayant et al. JAMA Oncology
- Disclosure—in the blink of an eye
- (2018) I F Tannock ANNALS OF ONCOLOGY
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
- (2018) Alyson Haslam et al. EUROPEAN JOURNAL OF CANCER
- Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs?
- (2018) Ravi B. Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology
- (2018) Bruno Kovic et al. JAMA Internal Medicine
- Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit
- (2017) N. Grössmann et al. EUROPEAN JOURNAL OF CANCER
- Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
- (2017) Ariadna Tibau et al. JNCI-Journal of the National Cancer Institute
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
- (2017) Joseph C Del Paggio et al. LANCET ONCOLOGY
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature
- (2017) Eric Lu et al. SEMINARS IN ONCOLOGY
- Financial conflicts of interest among editorialists in high-impact journals
- (2017) V Kaestner et al. Blood Cancer Journal
- Do cancer drugs improve survival or quality of life?
- (2017) Vinay Prasad BMJ-British Medical Journal
- Cancer drugs: high price, uncertain value
- (2017) Deborah Cohen BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
- (2017) Alison M Pease et al. BMJ-British Medical Journal
- Do cancer drugs improve survival or quality of life?
- (2017) Vinay Prasad BMJ-British Medical Journal
- Cancer drugs: high price, uncertain value
- (2017) Deborah Cohen BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
- (2017) Alison M Pease et al. BMJ-British Medical Journal
- Clinicians’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests
- (2017) Tammy C. Hoffmann et al. JAMA Internal Medicine
- Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
- (2017) Ariadna Tibau et al. JNCI-Journal of the National Cancer Institute
- Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines
- (2017) Sebastian Salas-Vega et al. JAMA Oncology
- Statistical controversies in clinical research: Publication bias evaluations are not routinely conducted in clinical oncology systematic reviews
- (2016) D. Herrmann et al. ANNALS OF ONCOLOGY
- Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
- (2016) J. C. Del Paggio et al. ANNALS OF ONCOLOGY
- Bias in reporting of randomised clinical trials in oncology
- (2016) Francisco E. Vera-Badillo et al. EUROPEAN JOURNAL OF CANCER
- Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes
- (2016) Lawrence N. Shulman et al. JOURNAL OF CLINICAL ONCOLOGY
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
- (2016) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
- (2016) William D Tap et al. LANCET
- Relevance of randomised controlled trials in oncology
- (2016) Ian F Tannock et al. LANCET ONCOLOGY
- Under-reporting of harm in clinical trials
- (2016) Bostjan Seruga et al. LANCET ONCOLOGY
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
- (2016) Anthony J Hatswell et al. BMJ Open
- Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment
- (2016) Myura Nagendran et al. BMJ-British Medical Journal
- Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment
- (2016) Myura Nagendran et al. BMJ-British Medical Journal
- Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials
- (2015) Fabio Efficace et al. CANCER
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology
- (2015) Kanwal Pratap Singh Raghav et al. JOURNAL OF CLINICAL ONCOLOGY
- Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs
- (2015) Ariadna Tibau et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer
- (2015) Andrea C. Enzinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
- (2015) Chul Kim et al. JAMA Internal Medicine
- Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
- (2015) Holly G. Prigerson et al. JAMA Oncology
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy
- (2014) O. Bylicki et al. ANNALS OF ONCOLOGY
- Reanalyses of Randomized Clinical Trial Data
- (2014) Shanil Ebrahim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
- (2014) Nicholas S. Downing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impact of Spin in the Abstracts of Articles Reporting Results of Randomized Controlled Trials in the Field of Cancer: The SPIIN Randomized Controlled Trial
- (2014) Isabelle Boutron et al. JOURNAL OF CLINICAL ONCOLOGY
- Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
- (2014) Tito Fojo et al. JAMA Otolaryngology-Head & Neck Surgery
- Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands
- (2013) Linda Mol et al. ACTA ONCOLOGICA
- Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
- (2013) F. E. Vera-Badillo et al. ANNALS OF ONCOLOGY
- Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials*
- (2013) A. J. Templeton et al. ANNALS OF ONCOLOGY
- Reporting of Patient-Reported Outcomes in Randomized Trials
- (2013) Melanie Calvert et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer
- (2012) Abdullah K. Altwairgi et al. JOURNAL OF CLINICAL ONCOLOGY
- Misrepresentation of Randomized Controlled Trials in Press Releases and News Coverage: A Cohort Study
- (2012) Amélie Yavchitz et al. PLOS MEDICINE
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
- (2011) Xavier Pivot et al. EUROPEAN JOURNAL OF CANCER
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical Practice
- (2011) Vincent C. Tam et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
- (2011) John R. Johnson et al. JNCI-Journal of the National Cancer Institute
- Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health
- (2010) Alexi A. Wright et al. JOURNAL OF CLINICAL ONCOLOGY
- What Is Value in Health Care?
- (2010) Michael E. Porter NEW ENGLAND JOURNAL OF MEDICINE
- Industry sponsorship and selection of comparators in randomized clinical trials
- (2009) D. N. Lathyris et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started